Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 104 participants.
Also called NCT03081598
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 104 participants
- Sponsor
- Liminal BioSciences Ltd.
- Registry
-
NCT03081598
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Terminated
Technical summary
Registry record NCT03081598. Randomized; quadruple masking; primary purpose treatment. Start 2017-05-29 (actual); primary completion 2018-09-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Metabolic Syndrome
- Intervention (Drug)
- PBI-4050
- Intervention (Other)
- Placebo
- Lead sponsor
- Liminal BioSciences Ltd.
Record details
- Record id
cardio:ct-nct03081598- Content hash
cf38827ec1269181e9a20bc26e6cb16f148f5675cb29f252f5ac3a6f2f9c4bde